메뉴 건너뛰기
Lancet Oncology
Volumn 7, Issue 6, 2006, Pages 447-449
Bisphosphonates and phossy-jaw: breathing new life into an old problem
Author keywords

[No Author keywords available]
Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENUSOMAB; NITROGEN DERIVATIVE; UNCLASSIFIED DRUG;
EID: 33646868829     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70704-5     Document Type: Letter
Times cited : (14)
References (8)
  • 1
    • 33646890244 scopus 로고    scopus 로고
    • Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment
    • Migliorati C., Siegel M., and Elting L. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7 (2006) 508-514
    • (2006) Lancet Oncol , vol.7 , pp. 508-514
    • Migliorati, C.1    Siegel, M.2    Elting, L.3
  • 2
    • 0042861578 scopus 로고    scopus 로고
    • Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic
    • Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
    • (2003) J Oral Maxillofac Surg , vol.61 , pp. 1115-1117
    • Marx, R.1
  • 3
    • 27344453813 scopus 로고    scopus 로고
    • Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment
    • Marx R., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
    • (2005) J Oral Maxillofac Surg , vol.63 , pp. 1567-1575
    • Marx, R.1    Sawatari, Y.2    Fortin, M.3    Broumand, V.4
  • 4
    • 33644906138 scopus 로고    scopus 로고
    • Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors
    • Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
    • (2006) J Clin Oncol , vol.24 , pp. 945-952
    • Badros, A.1    Weikel, D.2    Salama, A.3
  • 5
    • 28844439011 scopus 로고    scopus 로고
    • Anti-tumour activity of zoledronic acid
    • Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev 31 suppl 3 (2005) 1-8
    • (2005) Cancer Treat Rev , vol.31 , Issue.SUPPL. 3 , pp. 1-8
    • Clezardin, P.1
  • 6
    • 0034885581 scopus 로고    scopus 로고
    • The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma
    • McCloskey E., Guest J., and Kanis J. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 61 (2001) 1253-1274
    • (2001) Drugs , vol.61 , pp. 1253-1274
    • McCloskey, E.1    Guest, J.2    Kanis, J.3
  • 7
    • 33644869566 scopus 로고    scopus 로고
    • Guidelines on the diagnosis and management of multiple myeloma 2005
    • Smith A., Wisloff F., and Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 132 (2006) 410-451
    • (2006) Br J Haematol , vol.132 , pp. 410-451
    • Smith, A.1    Wisloff, F.2    Samson, D.3
  • 8
    • 33644760436 scopus 로고    scopus 로고
    • A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
    • Body J., Facon T., Coleman R., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12 (2006) 1221-1228
    • (2006) Clin Cancer Res , vol.12 , pp. 1221-1228
    • Body, J.1    Facon, T.2    Coleman, R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.